GRAL
GRAIL, Inc.
NASDAQ · USHealthcareMedical - Diagnostics & Research
$68.91-5.11%
Price as of Jul 20, 2026
GRAL profitability
GRAIL, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- -14.8%
- EBITDA margin
- -216.3%
- EBIT margin
- -348.7%
- Net margin
- -253.2%
- Free cash flow margin
- -186.7%
Returns
- Return on equity
- -15.8%
- Return on assets
- -14.1%
- Return on invested capital
- -21.3%
- Asset turnover
- 0.05x
Cash efficiency
- Cash from operations
- -$291.0M
- Cash per share
- $19
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.